Here's a question almost nobody in the psychedelic research world wants to sit with for long: what if the thing we're measuring isn't the thing that heals?

For the last fifteen years or so, the dominant story about psychedelics and healing has gone something like this. You take a high dose of psilocybin in a clinical setting. You have what researchers call a mystical-unitive experience — ego dissolution, a sense of merging with something vast, a transcendence of time and space. Afterwards, your depression lifts. Your addiction loosens. Your fear of dying softens. The more mystical the trip, the better the outcome. Simple.

Except Rick Strassman — the psychiatrist whose DMT research in the early 1990s is often credited with cracking open this entire renaissance — doesn't quite buy it. And when the person who ran the first federally approved psychedelic study in decades starts raising eyebrows at the field's central measuring stick, it's worth paying attention.

Why Strassman's Doubts Matter

Strassman isn't a skeptic from the outside. He's a Zen practitioner of more than two decades. He went into his DMT work expecting to see classic mystical states — the white light, the oneness, the ineffable merge with ultimate reality. That's what high-dose psychedelics were supposed to produce, especially the molecule often called the most potent psychedelic known.

From 1990 to 1995 he gave intravenous DMT to around sixty volunteers at the University of New Mexico. The study inspired his book DMT: The Spirit Molecule and, later, a documentary of the same name. Many of his subjects had profound, world-altering experiences. But here's the kicker: almost none of them reported what the field now defines as a mystical experience.

Out of roughly five dozen people, exactly one had something resembling the classic mystical-unitive state. One. And that volunteer happened to be a religious studies major who had been chasing such an experience for years.

What His Volunteers Actually Reported

Instead of dissolving into undifferentiated oneness, Strassman's volunteers kept their sense of self intact. They described slipping into a highly articulated place that felt inhabited — populated by beings, entities, intelligences. They asked questions. They got answers. The place felt, in their words, more real than ordinary reality.

This is not what the mystical experience questionnaire — the standard measurement tool used in modern psilocybin trials — is designed to pick up. That survey asks about transcendence of space and time, internal unity, a merge with ultimate reality. It's calibrated for a particular flavor of experience, one that fits neatly into a specific theological frame.

The Hidden Assumptions Baked Into Psychedelic Science

Where does the mystical-experience model come from? Not from the plants themselves. It comes from a lineage of thought that gained traction in the 1960s, particularly through research at Harvard and at the University of Maryland's Spring Grove Hospital. The researchers there treated alcoholism and end-of-life distress with high-dose LSD, and their results were strong. Their framework — rooted in transpersonal psychology, Eastern religious ideas, and psychodynamic theory — set the template that most current psilocybin studies still follow.

The Maryland group's data looked clean. Other researchers at the time were running wildly different protocols — low doses, high doses, no supervision, aversive settings — and getting results that were hard to compare. The Maryland model won by being coherent, not necessarily by being the only thing that works.

And this is Strassman's quiet point. The field didn't converge on the mystical model because exhaustive research proved it was the only path to therapeutic benefit. It converged because one well-run program made it the default, and nobody has seriously tested the alternatives since.

What Else Might Heal

If an interactive, relational experience — talking with beings, getting information from something that feels Other — is also a legitimate spiritual encounter, maybe it also drives healing. We just don't know, because almost nobody is running protocols designed to encourage or integrate that kind of experience. The infrastructure is built around the mystical-unitive frame. Preparation sessions prime you for it. Integration sessions help you make sense of it. The questionnaires measure it.

If you have a different kind of experience — one with entities, with dialogue, with distinct intelligences — the current research scaffolding doesn't quite know what to do with you. You'd probably be counted as having had a less successful session, even if your life changed afterwards.

Psychedelics as Super-Placebos

One of Strassman's more provocative framings is calling psychedelics super-placebos. He doesn't mean this dismissively. The placebo effect is a real biological phenomenon — expectation, belief, and context genuinely change what happens in the body. If a psychedelic maximally activates that capacity, that's not a bug. That's a tool.

Which raises an uncomfortable question for anyone considering a ceremony or retreat: how much of what you'll experience is shaped by what you've been told to expect?

If you've read every ayahuasca memoir and watched every documentary about mother-plant visions, chances are decent that mother will show up in your ceremony. If you've been steeped in DMT lore about machine elves, don't be shocked if something elf-shaped greets you. This doesn't mean the experiences are fake. It means consciousness under these substances is wildly suggestible, and the frame you bring in matters more than most retreat marketing is willing to admit.

Does It Matter If the Healing Came From Expectation?

Honestly, probably not — if the healing is real and durable. A person recovering from addiction who credits an encounter with a plant spirit isn't wrong to credit it, even if a neuroscientist would describe the same event in different language. What matters practically is whether the person stayed sober, whether their depression lifted, whether the trauma loosened its grip.

But it does matter for how we design studies, how we train facilitators, and how retreats pitch themselves to the people walking through the door.

What This Means If You're Considering a Retreat

If you're reading this because you're weighing an ayahuasca retreat or some other plant medicine journey — maybe for addiction, maybe for depression, maybe because something in your life has quietly ground to a halt — Strassman's work has a few practical implications worth sitting with.

• Your experience may not match the brochure. If you don't dissolve into cosmic unity, you haven't failed. Interactive, relational, visionary experiences are legitimate and may be equally therapeutic.
• What you're told beforehand shapes what you'll see. Pay attention to how a facilitator or retreat frames the experience. Heavy-handed priming — “you will meet Mother Ayahuasca and she will show you X” — is doing a lot of work on your expectations.
• Integration matters more than the trip itself. Across every therapeutic model, the thing that converts a powerful experience into lasting change is what you do with it afterwards. A retreat that drops you back at the airport with no follow-up is selling you half the medicine.
• Mystical isn't the only valid outcome. Grief surfacing, a difficult memory finally landing, a conversation with something that feels like a presence — these are real too, and they can shift stuck patterns.
• The research is young and the measurements are rough. Promising, yes. Settled science, no. Approach the whole space with curiosity and healthy skepticism in equal measure.

Choosing Carefully

Reputable retreats, in my experience, don't promise the mystical. They don't guarantee you'll heal. They prepare you, hold space without heavy-handed scripting, and give you tools for the weeks and months after you fly home. If a program is making specific promises about what you'll see or what you'll feel or how fixed you'll be, that's a red flag — not because psychedelics can't do profound work, but because the honest practitioners know how variable the terrain is.

Where the Movement Goes From Here

Strassman is one of several voices quietly pushing the field to broaden its lens. Master plants like ayahuasca, San Pedro, and iboga have been working with human consciousness for far longer than Western clinical frameworks have existed, and the indigenous traditions around them rarely reduce the experience to a single peak state. They talk about relationships — with the plant, with ancestors, with spirits, with the land. They talk about discipline, dieta, long apprenticeships. They talk about work that unfolds over years.

Western psychedelic science is slowly, awkwardly catching up to the idea that a six-hour session, however intense, isn't the whole story. The questionnaire is a crude instrument. The mystical-unitive frame captures something real but not everything real. And the quiet, relational, sometimes strange encounters that happen in ceremony may turn out to be just as medicinal as the dissolution-into-light experiences that get all the ink.

None of this should scare you off exploring plant medicine if you're genuinely called to it. If anything, it should make you a more discerning seeker — someone who shows up curious rather than script-ready, and who evaluates a retreat on the quality of its preparation and integration rather than the promises on its homepage. For readers who want to take this further, a range of curated ayahuasca and plant medicine retreats can be browsed on our marketplace here.

The honest work, as Strassman keeps reminding us, is figuring out what actually heals — not just what fits the model.